^
    Back
    Association details:
    Biomarker:MTOR M2327I
    Cancer:Breast Cancer
    Drug:Opsiria (sirolimus) (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Nature
    Title:

    Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor

    Published date:
    05/18/2016
    Excerpt:
    ...xenografts with MCF-7 cells expressing the TKi-R mutant, M2327I mTOR, showed significantly less sensitivity to AZD8055 treatment, yet retained full sensitivity to rapamycin and RapaLink-1.
    DOI:
    10.1038/nature17963